It is a long established fact that a reader of a page when looking at its layout.

    Tumor analysis. Determine course of care.

    Identify potential candidates for additional therapy.

    SmartKidney Dx™, in the final stage of development, is a biomarker- and algorithm-based direct tissue measurement that potentially predicts the presence or the risk of metastases.

    Personalized Healthcare

    • SmartKidney Dx is designed with the intention of identifying patients who are candidates for additional therapy, due to undiagnosed micro-metastases by the current standard of care.
    • This test aims to help accelerate the course of treatment by reducing risk of disease progression through early intervention.
    • Partnered and collaborated on the development of SmartKidney Dx with Mayo Clinic and licensed with Mayo Ventures.